683 Capital Management, LLC Cellectis S.A. Transaction History

683 Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.45 - $8.77 $1.22 Million - $3.09 Million	-352,638 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.01 - $12.84 $2.34 Million - $3.76 Million	292,738 Added 488.71%	352,638 $2.86 Million
Q1 2021 May 17, 2021	SELL	$18.19 - $33.25 $2.83 Million - $5.17 Million	-155,486 Reduced 72.19%	59,900 $1.21 Million
Q4 2020 Feb 16, 2021	BUY	$15.87 - $31.64 $244,175 - $486,813	15,386 Added 7.69%	215,386 $5.83 Million
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $1.64 Million - $4.2 Million	200,000 New	200,000 $3.56 Million

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.